NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
Endeavor Biomedicines, Inc.
University Hospital, Lille
PrECOG, LLC.
Lumicell, Inc.
Fundación GECP